跳至主要内容
临床试验/2024-518943-38-00
2024-518943-38-00招募中3 期

KETALGIA : Evaluation of the effectiveness of a ketamine infusion combined with magnesium sulfate in the treatment of chronic refractory cluster headache

University Hospital Of Clermont-Ferrand14 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2024年12月3日最近更新:

试验速览

阶段
3 期
状态
招募中
发起方
入组人数
90
试验地点
14
主要终点
Change in weekly frequency of crisis over the period D7-D13 compared to the pre-treatment period

研究概览

简要总结

Evaluate the efficacy of a single infusion of ketamine combined with magnesium sulfate compared to a control group receiving hydroxyzine (active placebo)

研究设计

分配方式
Randomized
主要目的
Allocation du traitement
盲法
Double (Monitor, Subject, Investigator)

入排标准

年龄范围
18 years 至 65+ years(18-64 Years, 65+ Years)
接受健康志愿者

入选标准

  • Age ≥ 18 years
  • Diagnosis of chronic cluster headache according to ICHD-3 criteria
  • Presence of at least 2 crises/24 hours on average during the 14 days preceding the ketamine infusion
  • Insufficient effectiveness, intolerance or contraindication to the use of the 3 major treatments for the management of cluster headaches: verapamil, lithium and corticosteroids (oral or suboccipital injections)
  • informed consent

排除标准

  • Pregnant or breastfeeding woman
  • Contraindication to the use of ketamine
  • Use of ketamine in the year preceding the study
  • Severe renal failure
  • Severe liver failure
  • Implementation or modification of an analgesic treatment (background treatments) in the 7 days preceding the infusion
  • Patient under legal protection measure
  • Addictive behaviors
  • Corrected QT > 450ms

结局指标

主要结局

Change in weekly frequency of crisis over the period D7-D13 compared to the pre-treatment period

Change in weekly frequency of crisis over the period D7-D13 compared to the pre-treatment period

次要结局

  • Change in weekly frequency of crisis over the period D14-D20, D21-D27, D28-D34 compared to the pre-treatment period
  • The proportion of responders at 30%, 50% and 75% each week post-infusion
  • Response to treatment according to initial serum magnesium
  • The weekly frequency and intensity of crisis between the 7 days preceding the infusion and each week post infusion
  • Crisis treatments intake
  • Anxiety and depression scoring (HAD)
  • The PGIC scoring for the overall clinical evaluation on D15 and D90
  • The proportion of patients requiring additional treatment on D15
  • Direct medical costs
  • Evaluation of adverse effects
  • Evaluation of blinding quality

研究者

发起方
University Hospital Of Clermont-Ferrand
申办方类型
Hospital/Clinic/Other health care facility
责任方
Principal Investigator
主要研究者

Lise Laclautre

Scientific

University Hospital Of Clermont-Ferrand

研究点 (14)

Loading locations...

相似试验

Re-purposing of 2 well-known molecules (ketamine and... | 临床试验